BURLINGTON, N.C., Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.  About LabcorpLabcorp (NYSE: LH) is a global leader of innovative a ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Labcorp (LH) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat.This medical laboratory operator has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 2.40%.Fo ...

BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2025, to stockholders of record as of the close of business on February 27, 2025.About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospita ...

BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.The call w ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Labcorp Holdings Inc. (LH) , or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and innovation to lead in important therapeutic areas. Moreover, the LaunchPad initiative is contributing to strong margin performance. Yet, the adverse macroeconomic impacts and currency fluctuations may dent its growth.In the past year, this Zacks Rank #3 (Hold) stock has risen 1.3% compared with the 1.2% grow ...

公司动态 - Labcorp与Graves Gilbert Clinic达成全面战略协议 旨在降低成本 提高服务质量 巩固其作为高价值医疗服务提供者的地位 [9] - Labcorp与MAWD Pathology Group达成协议 收购其临床和女性健康检测业务的部分资产 此前还完成了对Ballad Health部分实验室服务的收购 旨在提升阿巴拉契亚地区社区的高质量实验室服务 [18] - Labcorp宣布其新型H5禽流感分子检测在美国商业上市 该检测由CDC支持开发 旨在提高检测能力 支持公共卫生准备策略 [5] 市场表现 - Labcorp股价自12月19日宣布消息以来上涨1.1% 收于229.49美元 [2] - 过去三个月 Labcorp股价上涨3.4% 高于行业1.2%的涨幅 [6] - Labcorp市值为191.9亿美元 预计收益增长7.1% 收入增长0.7% 过去四个季度均超出收益预期 平均超出2.87% [16] 行业前景 - 2023年全球临床实验室服务市场规模为2332.4亿美元 预计到2030年将以3.5%的年复合增长率增长 [4] - 市场增长驱动因素包括慢性疾病负担增加 早期诊断测试需求增长 以及数据管理和样本制备技术的快速进步 [17] 合作伙伴与战略 - Labcorp与多家地方和区域卫生系统建立战略合作 增强对患者和医疗服务提供者的服务 [1] - Labcorp与Graves Gilbert Clinic的合作将结合双方的重要能力 经验和技术 提升实验室服务 推动高质量护理的提供 [3] - Labcorp通过成为卫生系统和区域实验室的首选合作伙伴 利用科学和创新扩展在重要治疗领域的领导地位 并利用数据和技术为客户提供重要服务和能力 [2] 其他公司表现 - Phibro Animal Health的2025财年每股收益预期在过去30天内增长1.9%至1.62美元 过去一年股价上涨85.6% 超出行业11.3%的涨幅 过去四个季度均超出收益预期 平均超出25.47% 最近一个季度超出52.17% [8] - Haemonetics的2025财年每股收益预期在过去30天内保持不变 为4.59美元 过去一年股价下跌10.9% 过去四个季度中有三个季度超出收益预期 平均超出2.82% 最近一个季度超出2.75% [15] - Penumbra的2024年每股收益预期在过去30天内增长2美分至2.81美元 过去一年股价下跌7.6% 过去四个季度中有三个季度超出收益预期 平均超出10.54% 最近一个季度超出23.19% [19]

Labcorp (LH) recently announced the commercial availability of its new H5 bird flu molecular test in the United States. The test will help physicians diagnose patients suspected of infection with the H5N1 virus.The test was developed in collaboration with the CDC (Centers for Disease Control and Prevention) to support public health preparedness strategies.LH Stock’s Likely Trend Following the NewsSince the announcement on Dec. 17, Labcorp shares have fallen 2%, finishing at $226.31 yesterday. On a promising ...

Labcorp Holdings, Inc. (LH) has entered into an agreement with MAWD Pathology Group in Lenexa, KS, to acquire select assets of its clinical and women’s health testing businesses. Both companies share a commitment to improving community health through high-quality laboratory services.The transaction is anticipated to close in early 2025, subject to customary closing conditions.  In the meantime, operations or services will remain unchanged.LH Stock’s Likely Trend Following the NewsFollowing the announcement ...

New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C., Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu. The test is available in the United States to physicians to order for patients suspect ...